Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma
Brain Tumor Pathology · 2021-10 · 38 (4) · 271-282
DOI: 10.1007/s10014-021-00411-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Tumor Pathology, online erschienen am 02.08.2021. Verfasst von Seong-Ik Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Hospital, College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 110-799, South Korea. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Oligodendroglioma, Vimentin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Ministry of Health and Welfare.
Abstract (Originalsprache)
Vimentin is a marker of epithelial-mesenchymal transformation and indicates poor prognosis in various cancers, but its role in diffuse gliomas remains unknown. We investigated the vimentin expression of diffuse gliomas according to the upcoming 2021 WHO classification, its variations due to mutational status, and its prognostic effects. We analyzed vimentin immunohistochemistry in 315 gliomas: a test set (n = 164) and a validation set (n = 151). RNA-seq and mutational information from The Cancer Genome Atlas (TCGA, n = 422) were also used for validation. Vimentin was diffusely positive in astrocytic tumors but negative in oligodendroglial tumors (ODGs) and its expression was significantly higher in isocitrate dehydrogenase (IDH) wild-type tumors. High vimentin expression was correlated with poor prognosis (hazard ratio [HR]: 5.99), but it was dependent on the new WHO grade which reflects both histologic features and genetics (HR: 1.28). Using the significant difference in vimentin expression between ODGs and astrocytic tumors, the positive and negative predictive values of the vimentin-based diagnosis for ODGs were 93.5% and 97.8% in the validation set. Along with additional alpha-thalassemia/mental retardation, X-linked (ATRX) immunohistostaining, the values were 98.3% and 97.8%, respectively. Vimentin is a useful ancillary marker for identifying ODGs when combined with routine histochemistry markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Seoul National University Hospital, College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 110-799, South Korea.
- Center for Precision Medicine, Seoul National University Hospital, Seoul, 03080, South Korea.
- Department of Neurosurgery, Seoul National University Hospital, College of Medicine, Seoul, 03080, South Korea.
- Department of Radiology, Seoul National University Hospital, College of Medicine, Seoul, 03080, South Korea.
- Neuroscience Institute, Seoul National University College of Medicine, Seoul, 03080, South Korea.
- Department of Pathology, Seoul National University Hospital, College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 110-799, South Korea. jkwon@snuh.org.
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Kim, S. I., Lee, K., Bae, J., Lee, S., Yun, H., Park, C. K., Choi, S. H., Maquiling, C. A., Park, S. H., & Won, J. K. (2021). Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma. Brain Tumor Pathology, 38(4), 271-282. https://doi.org/10.1007/s10014-021-00411-4
Vancouver
Kim SI, Lee K, Bae J, Lee S, Yun H, Park CK, et al. Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma. Brain Tumor Pathology. 2021;38(4):271-282. doi:10.1007/s10014-021-00411-4
BibTeX
@article{Kim2021,
author = {Kim, Seong-Ik and Lee, Kwanghoon and Bae, Jeongmo and Lee, Sungyoung and Yun, Hongseok and Park, Chul-Kee and Choi, Seung Hong and Maquiling, Christopher Alec and Park, Sung-Hye and Won, Jae-Kyung},
title = {Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma},
journal = {Brain Tumor Pathology},
year = {2021},
volume = {38},
number = {4},
pages = {271--282},
doi = {10.1007/s10014-021-00411-4}
}
EUVIMED